Drug made in Kalamazoo could be first to treat Parkinson’s | Woodtv.com

GRAND RAPIDS, Mich. (WOOD) — A diabetes drug developed in Kalamazoo is showing promise in treating Parkinson’s disease. The Van Andel Research Institute says human trials will begin next year for MSDC-0160, which was created […]

Read On ›

Van Andel Institute: Diabetes drug slows experimental Parkinson’s disease progression, human trials to begin next year

GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s […]

Read On ›

First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation

ST. LOUIS PARK, Minn., Nov. 09, 2016 (GLOBE NEWSWIRE) —  NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the first use […]

Read On ›

ConcertoHealth® Closes $30 Million Growth Financing; New Equity Will Fuel Expansion of Primary Care Medical Home Model and Population Health Platform

IRVINE, CA–(Marketwired – Nov 1, 2016) – ConcertoHealth, the nation’s leading provider of healthcare services for complex, frail, elderly, and Medicare-Medicaid dual-eligible patients, today announced the completion of a $30 million round of financing from […]

Read On ›

Sales near for Delphinus ultrasonic breast cancer detector

Delphinus Medical Technologies Inc. is about to graduate. And, after 17 years of research and development and three rounds of venture capital totaling $58.5 million, it will start selling its first devices for ultrasonic detection […]

Read On ›

NeoChord Receives FDA Approval to begin Clinical Trial for Treatment of Degenerative Mitral Valve Regurgitation

ST. LOUIS PARK, Minn.–(BUSINESS WIRE)–NeoChord, Inc. today announced that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to begin a prospective, multicenter, randomized clinical trial for […]

Read On ›

David H. Adams, MD and Michael A. Borger, MD, PhD to Serve as National Principal Investigators for NeoChord’s U.S. Pivotal Trial

ST. LOUIS PARK, Minn.–(BUSINESS WIRE)–NeoChord, Inc., a leader in advancing the treatment of minimally invasive repair of degenerative mitral valve regurgitation (DMR) without the use of cardiopulmonary bypass, today announced that David H. Adams, MD, […]

Read On ›